Rofecoxib

MUSCULO-SKELETAL SYSTEM

Key facts

Rofecoxib is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1999. DrugCentral lists 10 molecular targets, including Ptgs2, PTGER2 and PTGS2. Recorded indications include Dysmenorrhea, Juvenile rheumatoid arthritis, Migraine and Osteoarthritis.

• Approval status: ofm (first approved 1999 by the FDA).
• Molecular targets: Ptgs2, PTGER2, PTGS2 and PTGS2 (10 listed in DrugCentral).
• Indications: Dysmenorrhea, Juvenile rheumatoid arthritis, Migraine, Osteoarthritis and Pain and others.
• ATC code: M01AH02 (Coxibs).
• Molecular formula: C17H14O4S; molecular weight 314.36 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Dysmenorrhea
• Juvenile rheumatoid arthritis
• Migraine
• Osteoarthritis
• Pain
• Rheumatoid arthritis

Mechanism & targets

Molecular targets (10)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	Ptgs2	unknown	IC50 7.92
Prostaglandin E2 receptor EP2 subtype	PTGER2	unknown	Ki 7.47
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 6.52
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 6.51
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 6.37
Prostaglandin G/H synthase 2	Ptgs2	unknown	IC50 6.12
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 5.77
Cytochrome c oxidase subunit 2	MT-CO2	unknown	IC50 5.52
Prostaglandin G/H synthase 1	Ptgs1	unknown	IC50 4.94
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 4.63

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1999-05-20	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
M01AH02	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Coxibs

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	614.5
Oesophageal spasm	255.3
Acne cystic	249.1
Oesophageal pain	239.8
Lymphoedema	181.1
Stress	175.2
Drug intolerance	172.7
Drug ineffective	150.5
Sleep apnoea syndrome	138.0
Cystitis	111.6
Tinnitus	107.6
Anaphylactic reaction	100.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Rofecoxib is on its molecule page.

• Molecular formula: C₁₇H₁₄O₄S
• Molecular weight: 314.36 g/mol
• CAS number: 162011-90-7
• InChIKey: RZJQGNCSTQAWON-UHFFFAOYSA-N
• PubChem CID: 5090

CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Rofecoxib used for?

DrugCentral lists the following indications for Rofecoxib: Dysmenorrhea, Juvenile rheumatoid arthritis, Migraine, Osteoarthritis, Pain and Rheumatoid arthritis.

How does Rofecoxib work?

Its molecular targets in DrugCentral include Ptgs2, PTGER2, PTGS2 and PTGS2 (inhibitor).

When was Rofecoxib first approved?

Rofecoxib was first approved by the FDA in 1999.

What is the chemical formula of Rofecoxib?

Rofecoxib has the molecular formula C17H14O4S and a molecular weight of 314.36 g/mol.

Sources

• DrugCentral drug card 2397 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL122 — compound record and bioactivity
• PubChem CID 5090 — chemical identifiers
• DrugBank DB00533 — drug record
• FDA UNII 0QTW8Z7MCR — substance identity
• DailyMed: FDA labels for Rofecoxib — current prescribing information (label search)
• UniProt P43116 (PTGER2) — target protein
• UniProt P35354 (PTGS2) — target protein
• UniProt P23219 (PTGS1) — target protein
• UniProt P00403 (MT-CO2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.